We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information
Product name
Empagliflozin
CAS No.
864070-44-0
Molecular Formula
C23H27ClO7
Molecular Weight
450.91
Quality Standard
99.5% up by HPLC, Medical Grade
Appearance
White powder
COA of Empagliflozin
ITEMS
STANDARDS
RESULTS
Appearance
White to off-White Powder
Complies
Identification
HPLC
Complies
Melt Point
150 ~ 155 ℃
152.0 ~ 154.0 ℃
Loss on dry
≤0.5%
0.3%
Residue on ignition
≤0.1%
Complies
Heavy metals
≤10ppm
Complies
Water content
≤0.5%
0.32%
Optical rotation
+15 ~ +21
+19.5
Solubility in water
8-12mg/ 100ml
9mg/ 100ml
Solubility
soluble in methanol and DCM
Conformed
Related Substances
Total impurities ≤0.5%
Single impurity（max）≤0.1%
0.23%
0.04%
Isomer
≤0.15%
0.09%
Particle size
D90＜20μ m
Complies
Assay(HPLC)
≥99.5%
99.86%
Residual solvents
Ethyl acetate≤0.5%
0.20%
Dichloromethane≤0.6%
ND
Ethyl alcohol≤0.5%
0.03%
Methanol≤0.3%
ND
ACN≤0.041%
ND
Tetrahydrofurans≤0.072%
0.04%
Methylbenzene≤0.089%
0.06%
Conclusion
Complies with specification.
Usage
Function of Empagliflozin
Empagliflozin tablet is a new type of hypoglycemic drug, which can reduce the blood sugar level of patients and protect the liver and kidney function of patients. In addition, it also has a certain protective effect on the cardiovascular system of patients. When Empagliflozin tablets are used alone, patients often have lower blood sugar levels than before, and hypoglycemia rarely occurs. It is recommended that patients pay attention to monitoring the blood glucose level during the oral administration of Empagliflozin tablets. If Empagliflozin is used alone, the blood sugar level is not lowered well, it can also be combined with metformin or acarbose or other Hypoglycemic drugs.
Twenty years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
